Dr Reddy’s gets DCGI approval for Zytorvi
In short
Dr Reddy’s has received DCGI approval for Zytorvi. The drug is for first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
This could help Dr Reddy’s expand its cancer medicines business. The reporting does not say when the drug will be launched or what sales it may bring.
What the reporting says
Dr Reddy’s got DCGI approval for Zytorvi, a first-line treatment for adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The publisher summary confirms the indication, but it does not provide launch timing, pricing, or sales expectations. The approval could broaden Dr Reddy’s oncology portfolio, though the commercial impact is not stated.
Why it matters
Dr Reddy’s received DCGI approval for Zytorvi for first-line treatment of adult patients with unresectable advanced, recurrent or metastatic ESCC. The available reporting does not state launch timing, price, or expected revenue. The approval strengthens the company’s oncology pipeline and could matter for patients needing treatment options, but the business impact is not quantified.